Patents by Inventor Junliang Pan
Junliang Pan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20180334509Abstract: Isolated monoclonal antibodies that bind human tissue factor pathway inhibitor (TFPI) and the isolated nucleic acid molecules encoding them are provided. Pharmaceutical compositions comprising the anti-TFPI monoclonal antibodies and methods of treating deficiencies or defects in coagulation by administration of the antibodies are also provided. Methods of producing the antibodies are also provided.Type: ApplicationFiled: June 4, 2018Publication date: November 22, 2018Applicant: Bayer HealthCare LLCInventors: Zhuozhi WANG, John E. MURPHY, Junliang PAN, Haiyan Jiang, Bing LIU
-
Patent number: 10035840Abstract: Targeted coagulation factors comprising a coagulation factor linked with at least one domain that specifically binds to a membrane protein on a blood cell is provided. The disclosed targeted coagulation factors increase the efficiency of coagulation factors and prolong their duration of action and thus, are an improvement for the treatment of hematological diseases such as hemophilia A.Type: GrantFiled: July 28, 2016Date of Patent: July 31, 2018Assignee: Bayer HealthCare LLCInventors: Richard Feldman, Ji-Yun Kim, Haiyan Jiang, Kirk McLean, Junliang Pan, Glenn Pierce, James Wu, Xiao-Yan Zhao
-
Publication number: 20170342162Abstract: Isolated monoclonal antibodies that bind human tissue factor pathway inhibitor (TFPI) and the isolated nucleic acid molecules encoding them are provided. Pharmaceutical compositions comprising the anti-TFPI monoclonal antibodies and methods of treating deficiencies or defects in coagulation by administration of the antibodies are also provided. Methods of producing the antibodies are also provided.Type: ApplicationFiled: July 7, 2017Publication date: November 30, 2017Applicant: Bayer HealthCare LLCInventors: Zhuozhi WANG, John E. MURPHY, Junliang PAN, Haiyan Jiang, Bing LIU
-
Publication number: 20170051042Abstract: Targeted coagulation factors comprising a coagulation factor linked with at least one domain that specifically binds to a membrane protein on a blood cell is provided. The disclosed targeted coagulation factors increase the efficiency of coagulation factors and prolong their duration of action and thus, are an improvement for the treatment of hematological diseases such as hemophilia A.Type: ApplicationFiled: July 28, 2016Publication date: February 23, 2017Inventors: Richard FELDMAN, Ji-Yun KIM, Haiyan JIANG, Kirk MCLEAN, Junliang PAN, Glenn PIERCE, James WU, Xiao-Yan ZHAO
-
Patent number: 9422362Abstract: Targeted coagulation factors comprising a coagulation factor linked with at least one domain that specifically binds to a membrane protein on a blood cell is provided. The disclosed targeted coagulation factors increase the efficiency of coagulation factors and prolong their duration of action and thus, are an improvement for the treatment of hematological diseases such as hemophilia A.Type: GrantFiled: April 15, 2014Date of Patent: August 23, 2016Assignee: BAYER HEALTHCARE LLCInventors: Richard Feldman, Ji-Yun Kim, Haiyan Jiang, Kirk Mclean, Junliang Pan, Glenn Pierce, James Wu, Xiao-Yan Zhao
-
Patent number: 9309324Abstract: Isolated monoclonal antibodies that bind human tissue factor pathway inhibitor (TFPI) are provided. Isolated nucleic acid molecules encoding monoclonal antibodies that bind TFPI are also contemplated. Pharmaceutical compositions comprising the anti-TFPI monoclonal antibodies and methods of treating deficiencies or defects in coagulation by administration of the antibodies are also provided. Methods of producing the antibodies are also provided.Type: GrantFiled: March 1, 2011Date of Patent: April 12, 2016Assignee: BAYER HEALTHCARE LLCInventors: Zhuozhi Wang, Junliang Pan, Joanna Grudzinska, Christian Votsmeier, Jan Tebbe, Joerg Birkenfeld, Nina Wobst, Simone Brueckner, Susanne Steinig, Peter Scholz
-
Publication number: 20140221618Abstract: Targeted coagulation factors comprising a coagulation factor linked with at least one domain that specifically binds to a membrane protein on a blood cell is provided. The disclosed targeted coagulation factors increase the efficiency of coagulation factors and prolong their duration of action and thus, are an improvement for the treatment of hematological diseases such as hemophilia A.Type: ApplicationFiled: April 15, 2014Publication date: August 7, 2014Inventors: Richard Feldman, Ji-Yun Kim, Haiyan Jiang, Kirk Mclean, Junliang Pan, Glenn Pierce, James Wu, Xiao-Yan Zhao
-
Patent number: 8481030Abstract: Isolated monoclonal antibodies that bind human tissue factor pathway inhibitor (TFPI) are provided. Isolated nucleic acid molecules encoding monoclonal antibodies that bind TFPI are also contemplated. Pharmaceutical compositions comprising the anti-TFPI monoclonal antibodies and methods of treating deficiencies or defects in coagulation by administration of the antibodies are also provided. Methods of producing the antibodies are also provided.Type: GrantFiled: December 12, 2011Date of Patent: July 9, 2013Assignee: Bayer Healthcare LLCInventors: Zhuozhi Wang, Junliang Pan, Joanna Grudzinska, Christian Votsmeier, Jan Tebbe, Joerg Birkenfeld, Nina Wobst, Simone Brueckner, Susanne Steinig, Peter Scholz
-
Publication number: 20120329996Abstract: Isolated monoclonal antibodies that bind human tissue factor pathway inhibitor (TFPI) are provided. Isolated nucleic acid molecules encoding monoclonal antibodies that bind TFPI are also contemplated. Pharmaceutical compositions comprising the anti-TFPI monoclonal antibodies and methods of treating deficiencies or defects in coagulation by administration of the antibodies are also provided. Methods of producing the antibodies are also provided.Type: ApplicationFiled: March 1, 2011Publication date: December 27, 2012Inventors: Zhuozhi Wang, Junliang Pan, Joanna Grudzinska, Christian Votsmeier, Jan Tebbe, Joerg Birkenfeld, Nina Wobst, Simone Brueckner, Susanne Steinig, Peter Scholz
-
Publication number: 20120269817Abstract: Isolated monoclonal antibodies that bind human tissue factor pathway inhibitor (TFPI) and the isolated nucleic acid molecules encoding them are provided. Pharmaceutical compositions comprising the anti-TFPI monoclonal antibodies and methods of treating deficiencies or defects in coagulation by administration of the antibodies are also provided. Methods of producing the antibodies are also provided.Type: ApplicationFiled: August 4, 2009Publication date: October 25, 2012Applicant: BAYER HEALTHCARE LLCInventors: Zhuozhi Wang, John E. Murphy, Junliang Pan, Haiyan Jiang, Bing Liu
-
Publication number: 20120108796Abstract: Isolated monoclonal antibodies that bind human tissue factor pathway inhibitor (TFPI) are provided. Isolated nucleic acid molecules encoding monoclonal antibodies that bind TFPI are also contemplated. Pharmaceutical compositions comprising the anti-TFPI monoclonal antibodies and methods of treating deficiencies or defects in coagulation by administration of the antibodies are also provided. Methods of producing the antibodies are also provided.Type: ApplicationFiled: December 12, 2011Publication date: May 3, 2012Inventors: Zhuozhi WANG, Junliang Pan, Joanna Grudzinska, Christian Votsmeier, Jan Tebbe, Joerg Birkenfeld, Nina Wobst, Simone Brueckner, Susanne Steinig, Peter Scholz
-
Publication number: 20110286988Abstract: This invention relates to treatment of von Willebrand Disease by administration of Factor VIII muteins that are covalently bound, at a predefined site that is not an N-terminal amine, to one or more biocompatible polymers such as polyethylene glycol. The mutein conjugates retain FVIII procoagulant activity and have improved pharmacokinetic properties in subjects lacking von Willebrand Factor.Type: ApplicationFiled: June 4, 2009Publication date: November 24, 2011Applicant: BAYER HEALTHCARE LLCInventors: Haiyan Jiang, Glenn Pierce, John E. Murphy, Junliang Pan, Xin Zhang, Tongyao Liu
-
Publication number: 20110077202Abstract: Targeted coagulation factors comprising a coagulation factor linked with at least one domain that specifically binds to a membrane protein on a blood cell is provided. The disclosed targeted coagulation factors increase the efficiency of coagulation factors and prolong their duration of action and thus, are an improvement for the treatment of hematological diseases such as hemophilia A.Type: ApplicationFiled: May 15, 2009Publication date: March 31, 2011Applicant: BAYER HEALTHCARE LLCInventors: Richard Feldman, Ji-Yun Kim, Haiyan Jiang, Kirk Mclean, Junliang Pan, Glenn Pierce, James Wu, Xiao-Yan Zhao
-
Publication number: 20090286721Abstract: This invention relates to novel fusion proteins, comprising a targeting protein and a plasminogen activator, preferably an antibody that binds to P-selectin, operably linked to the plasminogen activator DSPAalpha1, or analogs, fragments, derivatives, or variants thereof, which are useful as thrombolytic agents. Pharmaceutical compositions containing these fusion proteins, methods of using these fusion proteins as thrombolytic agents, and processes for synthesizing these fusion proteins are also described herein.Type: ApplicationFiled: September 6, 2005Publication date: November 19, 2009Inventors: Junliang Pan, Qingyu Wu, Achim Schuttler, Annemarie Schuttler
-
Patent number: 6692922Abstract: The invention relates to the interaction of MEC with CCR3 and/or CCR10 and to agents (e.g., ligands, antibodies, antagonists, agonists, inhibitors, promoters) which alter said interaction. In one aspect, the invention relates to methods for detecting or identifying an agent (i.e., molecule or compound) which can modulate (inhibit, promote) the binding of MEC to CCR3 and/or CCR10. In another aspect, the invention relates to a method of treating a subject having an inflammatory condition, comprising administering to the subject an effective amount of an agent which modulates the binding of MEC to CCR3 and/or CCR10.Type: GrantFiled: August 15, 2001Date of Patent: February 17, 2004Assignees: The Board of Trustees of the Leland Stanford Junior University, Millennium Pharmaceuticals, Inc.Inventors: Eugene C. Butcher, Eric J. Kunkel, Junliang Pan, Dulce Soler-Ferrán
-
Publication number: 20030223976Abstract: This invention provides a novel expression control region isolated from mammalian corin genes. This control region preferentially activates transcription in cardiac cells. Methods and compositions are provided to employ this control region for identification of agents capable of modulating corin expression and for treatment of cardiac disease.Type: ApplicationFiled: May 28, 2003Publication date: December 4, 2003Applicant: Schering AktiengesellchaftInventors: Junliang Pan, Qingyu Wu
-
Publication number: 20020137107Abstract: The invention relates to the interaction of MEC with CCR3 and/or CCR10 and to agents (e.g., ligands, antibodies, antagonists, agonists, inhibitors, promoters) which alter said interaction. In one aspect, the invention relates to methods for detecting or identifying an agent (i.e., molecule or compound) which can modulate (inhibit, promote) the binding of MEC to CCR3 and/or CCR10. In another aspect, the invention relates to a method of treating a subject having an inflammatory condition, comprising administering to the subject an effective amount of an agent which modulates the binding of MEC to CCR3 and/or CCR10.Type: ApplicationFiled: August 15, 2001Publication date: September 26, 2002Applicant: Millennium Pharmaceuticals, Inc.Inventors: Eugene C. Butcher, Eric J. Kunkel, Junliang Pan, Dulce Soler-Ferran
-
Patent number: 5605821Abstract: DNA molecules and methods for the regulated expression of a gene in endothelial cells or megakaryocytes, are described, wherein the 5' flanking region of the P-selectin gene, or portions thereof, is ligated to the 5' end of a gene. The DNA molecules are also used as probes for screening individuals with abnormal levels of expression of P-selectin, or for production of pharmaceutical compositions to inhibit inflammation by inhibition of expression of P-selectin. These DNA molecules can also be used to identify and isolate previously unknown proteins which are involved in regulation of gene expression.Type: GrantFiled: August 20, 1993Date of Patent: February 25, 1997Assignee: Board of Regents of the University of OklahomaInventors: Rodger P. McEver, Junliang Pan
-
Patent number: RE47150Abstract: Isolated monoclonal antibodies that bind human tissue factor pathway inhibitor (TFPI) are provided. Isolated nucleic acid molecules encoding monoclonal antibodies that bind TFPI are also contemplated. Pharmaceutical compositions comprising the anti-TFPI monoclonal antibodies and methods of treating deficiencies or defects in coagulation by administration of the antibodies are also provided. Methods of producing the antibodies are also provided.Type: GrantFiled: July 12, 2016Date of Patent: December 4, 2018Assignee: Bayer HealthCare LLCInventors: Zhuozhi Wang, Junliang Pan, Joanna Grudzinska-Goebel, Christian Votsmeier, Jan Tebbe, Joerg Birkenfeld, Nina Wobst, Simone Brückner, Susanne Steinig, Peter Scholz